Patent US3465573A successfully refreshed from Google Patents.
Patent US3498900A successfully refreshed from Google Patents.
US4840941A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for inhibiting infection of human T-cells
Assignee: Ueno Seiyaku Oyo Kenkyujo KK
•
Filing: 1988-01-15
•
Granted: 1989-06-20
•
Expires: 2008-01-15
Abstract
Abstract Method of treatment of diseases caused by retroviruses which comprises administering therapeutically effective amount of a natural or synthetic oligo- or polysaccharide having at least one S-oxoacid group attached to the saccharic carbon atom through a linking group of lower molecular weight or a pharmaceutically acceptable salt thereof to a subject in need of such treatment.
Inventors
- 👤 Ryuzo Ueno
- 👤 Ryuji Ueno
- 👤 Sachiko Kuno
- 👤 Akihiko Tabata
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 13:58
CPC Classifications
C; C07; C07H; C07H11/00; A; A61; A61K; A61K31/00; A61K31/70; A61K31/715
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
45 words
A method for inhibiting infection of human T-cells by a human retrovirus which comprises providing in the presence of human T-cells susceptible to infection by said human retrovirus an infection inhibiting effective amount of dextran sulfate having a sulfur content of between 13 and 20%.
Claim 2
Independent Claim
45 words
A method for inhibiting infection of human T-cells by a human retrovirus which comprises providing in the presence of human T-cells susceptible to infection by said human retrovirus an infection inhibiting effective amount of dextran sulfate having a sulfur content of between 13 and 20%.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein said human retrovirus is a human immunodeficiency virus.
Claim 4
Dependent Claim
27 words
The method according to claim 1, wherein said human retrovirus is selected from the group consisting of human T-cell lymphotropic virus-III, lymphoadenopathy associated virus, and AIDS-related virus.
Claim 5
Dependent Claim
30 words
The method according to claim 1, wherein said human retrovirus is selected from the group consisting of human T-cell lymphotropic virus-I, human T-cell lymphotropic virus-II, and Kawasaki disease causative retroviruses.
Claim 6
Dependent Claim
18 words
The method of claim 1 wherein said dextran sulfate has a sulfur content of between 17 and 20%.
Claim 7
Dependent Claim
21 words
The method according to claim 1 or claim 5 wherein said dextran sulfate has a molecular weight between 500 and 2,000,000.
Claim 8
Dependent Claim
18 words
The method according to claim 6 wherein said dextran sulfate has a molecular weight between 2,000 and 300,000.
Claim 9
Dependent Claim
18 words
The method according to claim 6 wherein said dextran sulfate has a molecular weight between 2,000 and 10,000.
Claim 10
Dependent Claim
18 words
The method according to claim 6 wherein said dextran sulfate has a molecular weight between 2,000 and 8,000.
Claim 11
Dependent Claim
18 words
The method according to claim 6 wherein the dextran sulfate has a molecular weight between 2,000 and 6,000.
Claim 12
Dependent Claim
18 words
The method according to claim 6 wherein the dextran sulfate has a molecular weight between 7,000 to 8,000.
References Cited (Backward Citations)
CA1146859A
Cited
EP0066379A2
Cited
US4374832A
Cited
US4522814A
Cited
US4590181A
Cited
US4710493A
Cited
US4734403A
Cited
DE3601136A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-06-19 | 1992-12-19 | 1993-06-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-06-19 | 1996-12-19 | 1997-06-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-06-19 | 2000-12-19 | 2001-06-20 | $7700.00 | Window Closed / Lapsed |